Cargando…
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087531/ https://www.ncbi.nlm.nih.gov/pubmed/35895852 http://dx.doi.org/10.1111/bjd.21797 |
| _version_ | 1785022369220263936 |
|---|---|
| author | van der Schoot, Lara S. Atalay, Selma Otero, Marisol E. Kievit, Wietske van den Reek, Juul M.P.A. de Jong, Elke M.G.J. |
| author_facet | van der Schoot, Lara S. Atalay, Selma Otero, Marisol E. Kievit, Wietske van den Reek, Juul M.P.A. de Jong, Elke M.G.J. |
| author_sort | van der Schoot, Lara S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10087531 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100875312023-04-12 Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab van der Schoot, Lara S. Atalay, Selma Otero, Marisol E. Kievit, Wietske van den Reek, Juul M.P.A. de Jong, Elke M.G.J. Br J Dermatol Research Letters John Wiley and Sons Inc. 2022-08-20 2022-12 /pmc/articles/PMC10087531/ /pubmed/35895852 http://dx.doi.org/10.1111/bjd.21797 Text en © 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Research Letters van der Schoot, Lara S. Atalay, Selma Otero, Marisol E. Kievit, Wietske van den Reek, Juul M.P.A. de Jong, Elke M.G.J. Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| title | Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| title_full | Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| title_fullStr | Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| title_full_unstemmed | Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| title_short | Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| title_sort | regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab |
| topic | Research Letters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087531/ https://www.ncbi.nlm.nih.gov/pubmed/35895852 http://dx.doi.org/10.1111/bjd.21797 |
| work_keys_str_mv | AT vanderschootlaras regainingadequatetreatmentresponsesinpatientswithpsoriasiswhodiscontinueddosereductionofadalimumabetanerceptorustekinumab AT atalayselma regainingadequatetreatmentresponsesinpatientswithpsoriasiswhodiscontinueddosereductionofadalimumabetanerceptorustekinumab AT oteromarisole regainingadequatetreatmentresponsesinpatientswithpsoriasiswhodiscontinueddosereductionofadalimumabetanerceptorustekinumab AT kievitwietske regainingadequatetreatmentresponsesinpatientswithpsoriasiswhodiscontinueddosereductionofadalimumabetanerceptorustekinumab AT vandenreekjuulmpa regainingadequatetreatmentresponsesinpatientswithpsoriasiswhodiscontinueddosereductionofadalimumabetanerceptorustekinumab AT dejongelkemgj regainingadequatetreatmentresponsesinpatientswithpsoriasiswhodiscontinueddosereductionofadalimumabetanerceptorustekinumab |